Concurrent mutations of TERT and IDH predict good prognosis, as an alternative hallmark of oligodendroglioma, whereas TERT promoter mutation with wild-type IDH tends to be associated with poor prognosis, although its use in predicting outcomes in GBM is controversial [1, 6, 13, 15, 26, 30]. This evidence concerns the gene IDH2 and glioblastoma.